|
SEER SINQ Updates
Follow this link to a listing of SEER SINQ's that have been finalized during the months of January thru February 2024.
Highlights of this listing include:
-
20240008 instructs whether the term "diffuse" should be added to the CNS Solid Tumor Rules, Table 6: Specific Histologies, NOS and Subtypes/Variants, for papillary glioneuronal tumor 9509/1.
-
20240006 informs what the primary site and histology should be for a patient diagnosed with oropharyngeal soft tissue revealing plasma cell neoplasm with 5-10% marrow cellularity in 2022.
-
20230050 shares whether a diagnosis of Myofibroblastoma with sarcomatous transformation is reportable.
Click here to access the SEER SINQ Website.
| 
